PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
August 31, 2021 04:08 ET
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's...
Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013
November 19, 2013 06:35 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for
its clinical lead, RP6530, a novel, dual Phosphoinositide-3...